Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85 - NCT06155188Recruiting
New transplant method for childhood leukemia
This study tests a new combination of medicines to help donor cord blood cells grow better in children with leukemia after a transplant.
Guangzhou, GuangdongAges 1 month–18 years - NCT07862010RecruitingEarly Phase 1
Study of GI001 for B-cell lymphoma and leukemia that has returned or not responded
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
Yunnan, KunmingAges 18–75 - NCT07867600Recruiting
Lower-dose chemo for children with new leukemia
This trial tests a lower starting dose of chemotherapy for children newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. The goal is to see if a reduced dose is still effective and safer for children.
Asyut, Asyut GovernorateAges Up to 18 years - NCT07874100Recruiting
Personalized treatment for acute myeloid leukemia
This study looks for markers in your blood to help doctors choose the most effective treatment, especially a drug called venetoclax. By understanding your leukemia at a very detailed level, they hope to improve outcomes for you and others.
MilanAges 18 years+ - NCT01281735Recruiting
Study for children with Philadelphia-positive chronic leukemia
This trial is for children under 18 who have chronic myeloid leukemia (CML) with specific lab findings (Philadelphia-positive and/or BCR-ABL positive). It aims to test a treatment approach in pediatric patients with this form of CML.
North Adelaide, South AustraliaAges Up to 18 years - NCT06237192Recruiting
Treatment for adults with Ph-negative ALL
This trial tests a less intensive but continuous treatment approach for adults newly diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to improve outcomes by using minimal residual disease (MRD) to guide therapy.
MoscowAges 18–55 - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT07854652RecruitingPhase 1
Study of BEBT-908 for a rare subtype of acute lymphoblastic leukemia
This study tests whether the drug BEBT-908 can help people with a specific genetic change (MEF2D rearrangement) in their leukemia that has either come back, not responded to treatment, or left behind a small amount of disease. It aims to see how safe and effective the drug is in treating this subtype.
SuzhouAges 14–75 - NCT07313592Recruiting
Genome sequencing study for ALL patients
This study uses whole genome sequencing to analyze your leukemia's DNA. The goal is to find unique genetic changes that may help guide future treatments, though this study does not recommend any specific therapy.
St Louis, MissouriAges Up to 30 years - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Duarte, CaliforniaAges 18 years+ - NCT06329999Recruiting
CMGV for recurrent AML and high-risk MDS
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06339775RecruitingPhase 4
Blinatumomab for leukemia relapse after a stem cell transplant
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
Zhenzhou, HenanAges Up to 65 years - NCT05963061Recruiting
CML real-world patient data for people with chronic CML
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
AnnecyAges Any age - NCT06206174RecruitingPhase 1/Phase 2
Study of TGRX-814 for blood cancers
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04793919RecruitingPhase 2
Study of new treatment for youth with acute promyelocytic leukemia
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
BrusselsAges Up to 18 years - NCT03999723RecruitingPhase 2
Test azacitidine with vitamin C to improve DNA changes
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
AalborgAges 18 years+ - NCT06394011RecruitingPhase 2
New drug combo for intermediate/high risk AML
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
Suzhou, JiangsuAges 18–65 - NCT05439889Recruiting
Study of chronic myeloid leukemia patients in treatment-free remission
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
TaipeiAges 20 years+ - NCT06418776RecruitingPhase 3
Comparing treatments for AML that returns or doesn't respond
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
MoscowAges 18 years+ - NCT06225128Recruiting
How resistance to azacitidine-based therapy develops in AML
This study looks at how leukemia cells become resistant to two common drug combinations: azacitidine plus venetoclax or azacitidine plus ivosidenib. It is for people with newly diagnosed AML who are about to start one of these treatments.
ParisAges 18–100 - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT07838714RecruitingPhase 1
Cord blood CAR-T cells for relapsed B-cell leukemia
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05772559Recruiting
Study of AML genes and drug response in young patients
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
AmiensAges Up to 25 years
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.